Reasons it was discontinued (business, not safety) The decision to discontinue the commercial production of sermorelin was based on business reasons, not on its safety profiles
This could be due to two factors: Selection Bias: Patients prescribed 20 mg often have more severe underlying vascular disease (which necessitates the higher dose), potentially skewing their mortality risk higher regardless of the drug
The genetic test does not predict exact medication response or determine whether combination therapy will be beneficial for any individual patient
[DOI] [PubMed] [Google Scholar] 15.Nauck MA, Niedereichholz U, Ettler R, et al
In some people, particularly older adults or those with limited protein intake, both glycine and cysteine availability may constrain glutathione synthesis
Fabrication, microstructure and properties of a YSZ electrolyte for SOFCs